Some added perspective on the abstract. #msg-33270341 contains the abstract of the 1B monotherapy results of 191. The cohort of most relevance to the abstract is: 2 (naïve) 100 mg q8h 8 -1.7
The INFORM results presented of note is Group C (100mg q8 191 and 500mg BID 7128) with results presented as: the mean (SD [range]) change from baseline was -3.9 (0.8 [-5.0 to -2.9]) Log10 IU/mL, with 1 patient undetectable
Of note R7128 had much greater efficacy when dosing is at 1000mg BID and 191 at the 200mg dose which is planned to be tested in INFORM-1 (cohort D/Group F) had about a 2 log better performance then the 100mg q8 dose 4 (naïve) 200 mg q8h 8 -3.8
So in summary the synergy is very encouraging thus far. Of course the main concern was safety and if the combination would be tolerable and no mention of problems thus far.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.